Any current/future new fundraising through debt or equity?

There is no mention of any current or future fundraising through debt or equity in the provided transcript. The company discussed ongoing CAPEX plans, including expansions at Mahad and Baroda facilities and a hydrogenation facility commissioning, but no details on financing these through fundraising were provided. Net debt-equity ratio stands at 0.33 as of 30th September 2023, indicating manageable leverage. No direct references to plans for new debt or equity issuance were discussed during the Q&A or management comments.

Any current/future capex/capital investment/strategic investment?

The company has ongoing CAPEX plans which have been slightly downsized to ensure sustained profitability. The hydrogenation facility at Baroda has been optimized and is scheduled to be commissioned in Q4 FY24. The Mahad investment project is on track in terms of both timeline and budget. Expansion projects at Mahad and Baroda are expected to impact the revenue mix in the future, with a larger contribution anticipated from Specialty and Bulk Aroma Chemicals. Regarding new plants going live, it is still too early to confirm whether these are fully operational or at trial batch stages, with trial

Future growth expectations in sales/revenue/volumes?

The Fragrance and Flavor division is showing robust growth with new product launches, new customer wins, and expansion in all markets. Volume requirements for the First Half of 2024 are much better compared to H2-2023, indicating improved demand. Current revenue remains somewhat stagnant, but expansions at Mahad and Baroda facilities are expected to change the revenue mix and contribute to growth. Focus on profitable products and expansion in bulk and specialty aroma chemicals is expected to increase both volume and value. Camphor division volumes remain stable despite pricing pressure, with f

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects improvement in volume requirements for H2 FY24 compared to H2 FY23, indicating potential top-line growth. Robust growth is seen in the Fragrance and Flavor division with new product launches and new customer acquisitions. Specialty Aroma Ingredients and Camphor businesses remain under severe margin pressure; pricing and profitability challenges are expected to continue for a few more quarters. Margins have bottomed out but pricing pressure may persist; efforts are underway to optimize products and improve profitability. CAPEX projects at Mahad and Baroda are on trac

Current/ Expected Orderbook/ Pending Orders?

The transcript does not provide explicit details on the current or expected order book or pending orders in precise numbers. However, Dharmil Bodani mentions participation in global RFQs (Request for Quotations) with larger product volumes, indicating strong order pipeline activity. Volumes indicated in RFQs for the first half of 2024 are much better compared to H2-2023, signifying improving order momentum. The Fine Fragrance division is described as doing reasonably well with steady growth and new product wins. Camphor and Specialty Chemical divisions face pressure but continue operating at f

IN US

Sale is live|00:00:00left today

Oriental Aromatics LtdQ3 FY23Chemicals & Petrochemicals

Oriental Aromatics Ltd Q3 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹324P/E: 1440.7Market Cap: ₹1.1K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 4

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 4

→The Fragrance and Flavor division is showing robust growth with new product launches, new customer wins, and expansion in all markets.
→Volume requirements for the First Half of 2024 are much better compared to H2-2023, indicating improved demand.
→Current revenue remains somewhat stagnant, but expansions at Mahad and Baroda facilities are expected to change the revenue mix and contribute to growth.
→Focus on profitable products and expansion in bulk and specialty aroma chemicals is expected to increase both volume and value.
→Camphor division volumes remain stable despite pricing pressure, with full capacity utilization at the Bareilly plant.
→Overall, steady state demand is anticipated with expanding contribution from specialty and bulk aroma chemicals, supporting future top-line growth.

Margin guidance

Category 3

→The company expects improvement in volume requirements for H2 FY24 compared to H2 FY23, indicating potential top-line growth.
→Robust growth is seen in the Fragrance and Flavor division with new product launches and new customer acquisitions.
→Specialty Aroma Ingredients and Camphor businesses remain under severe margin pressure; pricing and profitability challenges are expected to continue for a few more quarters.
→Margins have bottomed out but pricing pressure may persist; efforts are underway to optimize products and improve profitability.
→CAPEX projects at Mahad and Baroda are on track, with some facilities commissioning in Q4 FY24, which could improve operational capacity and mix, thus aiding future growth.
→EBITDA margin improved slightly to 4.85% in Q2 FY24; net profit margins are low (~1%).
→Overall, growth will be driven by focus on profitable products, market expansion, and product mix changes, especially increased contributions from Specialty and Bulk Aroma Chemicals.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no mention of any current or future fundraising through debt or equity in the provided transcript.
→The company discussed ongoing CAPEX plans, including expansions at Mahad and Baroda facilities and a hydrogenation facility commissioning, but no details on financing these through fundraising were provided.
→Net debt-equity ratio stands at 0.33 as of 30th September 2023, indicating manageable leverage.
→No direct references to plans for new debt or equity issuance were discussed during the Q&A or management comments.

Order book

→The transcript does not provide explicit details on the current or expected order book or pending orders in precise numbers.
→However, Dharmil Bodani mentions participation in global RFQs (Request for Quotations) with larger product volumes, indicating strong order pipeline activity.
→Volumes indicated in RFQs for the first half of 2024 are much better compared to H2-2023, signifying improving order momentum.
→The Fine Fragrance division is described as doing reasonably well with steady growth and new product wins.
→Camphor and Specialty Chemical divisions face pressure but continue operating at full capacity (Bareilly plant), suggesting ongoing demand.
→CAPEX expansions at Mahad and Baroda are on track to possibly boost future order volumes once operational, although full commercial orders from these are still premature.
→Company remains optimistic about increasing bulk specialty vertical contribution to order book in the future.

Capex plans

Yes

→The company has ongoing CAPEX plans which have been slightly downsized to ensure sustained profitability.
→The hydrogenation facility at Baroda has been optimized and is scheduled to be commissioned in Q4 FY24.
→The Mahad investment project is on track in terms of both timeline and budget.
→Expansion projects at Mahad and Baroda are expected to impact the revenue mix in the future, with a larger contribution anticipated from Specialty and Bulk Aroma Chemicals.
→Regarding new plants going live, it is still too early to confirm whether these are fully operational or at trial batch stages, with trial batches and approvals typically taking around six months.

How does Oriental Aromatics Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Oriental Aromatics Ltd

Rev 4Mar 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Oriental Aromatics Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio